InvestingPro’s Fair Value model captures 63% gain in Steelcase ahead of acquisition
Lauren Mastrocola, Principal Accounting Officer at Praxis Precision Medicines, Inc. (NASDAQ:PRAX), sold 13,600 shares of common stock on November 20, 2025, for approximately $2.6 million. The sales were executed in multiple transactions with prices ranging from $191.958 to $192.711.
On the same day, Mastrocola also exercised options to acquire 13,100 shares of Praxis Precision Medicines common stock at prices ranging from $43.37 to $133.65, for a total value of $831257.
In other recent news, Praxis Precision Medicines announced a public offering of 3,025,480 shares of common stock priced at $157.00 per share, along with pre-funded warrants to purchase up to 318,470 shares. This offering is expected to generate approximately $525 million. Guggenheim has raised its price target for Praxis Precision Medicines to $540.00, maintaining a Buy rating due to progress in the company’s central nervous system drug candidates. The firm anticipates a potential FDA meeting later this year to discuss an NDA filing for ulixacaltamide, which could represent a significant sales opportunity.
Praxis has also reached alignment with the FDA on key aspects of its relutrigine development program for treating rare epilepsies, with plans for a New Drug Application submission in early 2026 if interim study results are positive. However, a recent short report from Culper Research has questioned the company’s Phase 3 trial results for its essential tremor treatment, alleging methodological changes and over-optimistic results. Despite these challenges, the company’s developments continue to attract attention from analysts and investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.